Scroll

telaprevir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
Hepatitis Virus C (HVC) protease inhibitors	4173	402957-28-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: telaprevir VX 950 incivek incivo	Telaprevir is an inhibitor of the HCV NS3/4A serine protease, necessary for the proteolytic cleavage of the HCV encoded polyprotein into mature forms of the NS4A, NS4B, NS5A and NS5B proteins and essential for viral replication. In a biochemical assay, telaprevir inhibited the proteolytic activity of the recombinant HCV NS3 protease domain with an IC50 value of 10 nM. Molecular weight: 679.86 Formula: C36H53N7O6 CLOGP: 5.39 LIPINSKI: 3 HAC: 13 HDO: 4 TPSA: 179.56 ALOGS: -4.28 ROTB: 14 Status: OFM Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

telaprevir
VX 950
incivek
incivo

Telaprevir is an inhibitor of the HCV NS3/4A serine protease, necessary for the proteolytic cleavage of the HCV encoded polyprotein into mature forms of the NS4A, NS4B, NS5A and NS5B proteins and essential for viral replication. In a biochemical assay, telaprevir inhibited the proteolytic activity of the recombinant HCV NS3 protease domain with an IC50 value of 10 nM.

Molecular weight: 679.86
Formula: C36H53N7O6
CLOGP: 5.39
LIPINSKI: 3
HAC: 13
HDO: 4
TPSA: 179.56
ALOGS: -4.28
ROTB: 14

Status: OFM

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
2.25	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Hosey CM, Chan R, Benet LZ
S (Water solubility)	0.00 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
Sept. 19, 2011	EMA	Janssen-Cilag International N.V.
May 23, 2011	FDA	VERTEX PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaemia	361.50	36.19	188	2217	293242	63193375
Pancytopenia	123.36	36.19	64	2341	96869	63389748
Rash	121.88	36.19	126	2279	560745	62925872
Aplastic anaemia	103.03	36.19	30	2375	9539	63477078
Thrombocytopenia	87.31	36.19	60	2345	151097	63335520
Anal pruritus	87.29	36.19	16	2389	651	63485966
Leukopenia	60.03	36.19	37	2368	77253	63409364
Haemoglobin decreased	45.05	36.19	40	2365	145445	63341172
Extradural abscess	40.87	36.19	9	2396	928	63485689
Drug reaction with eosinophilia and systemic symptoms	39.09	36.19	21	2384	33815	63452802
Neutropenia	38.76	36.19	40	2365	174965	63311652

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaemia	317.30	34.14	235	3603	233100	34719993
Rash	246.70	34.14	199	3639	222553	34730540
Pruritus	152.39	34.14	125	3713	141856	34811237
Depressed mood	76.86	34.14	39	3799	19278	34933815
Dry skin	74.43	34.14	45	3793	31242	34921851
Thrombocytopenia	73.70	34.14	88	3750	156159	34796934
Influenza like illness	71.60	34.14	42	3796	27592	34925501
Fatigue	53.52	34.14	122	3716	370531	34582562
Wrong dose	50.56	34.14	12	3826	587	34952506
Skin irritation	50.39	34.14	20	3818	5557	34947536
Anorectal discomfort	48.88	34.14	15	3823	1949	34951144
Leukopenia	42.74	34.14	43	3795	62813	34890280
Oral herpes	40.24	34.14	17	3821	5530	34947563
Anal pruritus	39.51	34.14	9	3829	367	34952726
Retinal exudates	38.01	34.14	10	3828	746	34952347
Porphyria non-acute	37.16	34.14	9	3829	480	34952613
Haemoglobin decreased	36.73	34.14	55	3783	120717	34832376
Retinopathy	35.88	34.14	12	3826	2052	34951041
Nausea	35.41	34.14	99	3739	339809	34613284
Pancytopenia	34.30	34.14	47	3791	95110	34857983
Acute stress disorder	34.23	34.14	7	3831	170	34952923

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaemia	588.54	33.88	370	5193	444645	79294180
Rash	265.40	33.88	258	5305	578100	79160725
Thrombocytopenia	163.15	33.88	140	5423	265119	79473706
Pancytopenia	143.47	33.88	107	5456	165638	79573187
Anal pruritus	121.61	33.88	24	5539	777	79738048
Pruritus	106.62	33.88	134	5429	394514	79344311
Leukopenia	95.75	33.88	73	5490	116440	79622385
Dry skin	84.75	33.88	55	5508	67940	79670885
Aplastic anaemia	83.01	33.88	35	5528	17870	79720955
Depressed mood	72.42	33.88	44	5519	48436	79690389
Haemoglobin decreased	70.52	33.88	82	5481	222037	79516788
Anorectal discomfort	63.42	33.88	19	5544	3592	79735233
Influenza like illness	54.64	33.88	43	5520	71664	79667161
Drug reaction with eosinophilia and systemic symptoms	49.97	33.88	39	5524	64205	79674620
Neutropenia	49.63	33.88	79	5484	287631	79451194
Fatigue	47.43	33.88	157	5406	929570	78809255
Dermatitis	47.08	33.88	25	5538	21296	79717529
Skin irritation	45.60	33.88	20	5543	11220	79727605
Wrong dose	43.58	33.88	12	5551	1682	79737143
Retinopathy	41.49	33.88	14	5549	3877	79734948
Toxic skin eruption	40.56	33.88	23	5540	22270	79716555
Hepatitis C	38.20	33.88	18	5545	11907	79726918
Hepatic failure	36.79	33.88	32	5531	61180	79677645

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J05AP02	ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HCV infections
FDA MoA	N0000182638	HCV NS3/4A Protease Inhibitors
FDA EPC	N0000182639	Hepatitis C Virus NS3/4A Protease Inhibitor
FDA MoA	N0000185503	P-Glycoprotein Inhibitors
FDA MoA	N0000190107	Organic Anion Transporting Polypeptide 1B1 Inhibitors
FDA MoA	N0000190109	Organic Anion Transporting Polypeptide 2B1 Inhibitors
FDA MoA	N0000190114	Cytochrome P450 3A Inhibitors
CHEBI has role	CHEBI:36044	antiviral drugs
CHEBI has role	CHEBI:63175	peptidomimetics
CHEBI has role	CHEBI:64924	hepatitis C protease inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Chronic hepatitis C	indication	128302006
Anemia	contraindication	271737000	DOID:2355

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	12.64	acidic
pKa2	13.65	acidic
pKa3	2.9	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
375MG	INCIVEK	VERTEX PHARMS	N201917	May 23, 2011	DISCN	TABLET	ORAL	8431615	May 30, 2028	METHOD OF TREATING CHRONIC HEPATITIS C

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Neutrophil elastase	Enzyme	P08246	ELNE_HUMAN		IC50	6.17	CHEMBL
Chymotrypsin-like elastase family member 1	Enzyme	Q9UNI1	CELA1_HUMAN		IC50	7.52	CHEMBL
Cathepsin B	Enzyme	P07858	CATB_HUMAN		IC50	6.68	CHEMBL
Cathepsin L1	Enzyme	P07711	CATL1_HUMAN		IC50	5.46	CHEMBL
Chymase	Enzyme	P23946	CMA1_HUMAN		IC50	7.59	CHEMBL
Lysosomal protective protein	Enzyme	P10619	PPGB_HUMAN	INHIBITOR	IC50	7	IUPHAR
Cathepsin L2	Enzyme	O60911	CATL2_HUMAN		IC50	5.87	CHEMBL
Cathepsin K	Enzyme	P43235	CATK_HUMAN		IC50	6.20	CHEMBL
Cathepsin S	Enzyme	P25774	CATS_HUMAN		IC50	6.52	CHEMBL
Plasminogen	Enzyme	P00747	PLMN_HUMAN		IC50	5.06	CHEMBL
Hepatitis C virus serine protease, NS3/NS4A	Enzyme		A3EZI9_9HEPC D2K2A8_9HEPC	INHIBITOR			CHEMBL	CHEMBL
Replicase polyprotein 1ab	Enzyme		R1AB_SARS2		IC50	4.94	CHEMBL
NS3 protease	Unclassified		C1KIQ2_9HEPC		IC50	6.89	CHEMBL
NS3 protease	Unclassified		Q0ZMF1_9HEPC		Ki	7.09	CHEMBL
NS3 protease	Unclassified		Q91RS4_9HEPC		Ki	8.41	CHEMBL

External reference:

ID	Source
4030729	VUID
N0000182739	NUI
D09012	KEGG_DRUG
4030729	VANDF
C1876229	UMLSCUI
CHEBI:68595	CHEBI
CHEMBL231813	ChEMBL_ID
DB05521	DRUGBANK_ID
C486464	MESH_SUPPLEMENTAL_RECORD_UI
7871	IUPHAR_LIGAND_ID
8686	INN_ID
655M5O3W0U	UNII
3010818	PUBCHEM_CID
1102261	RXNORM
181488	MMSL
27888	MMSL
d07777	MMSL
013797	NDDF
698806003	SNOMEDCT_US
704466001	SNOMEDCT_US
SV6	PDB_CHEM_ID

Pharmaceutical products:

None